/
/
/

Windlas Biotech Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
-16%21%19%
-33%16%9%
-23%46%14%
14%13%13%13%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
MANKIND
DRREDDY
AUROPHARMA
LUPIN
WINDLAS
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,849.9₹447476 Cr3712.0762.82₹11479 Cr
9,602₹254764 Cr87.134.04128.41₹2568 Cr
4,928.5₹189423 Cr86.8516.7297.06₹2163 Cr
1,180.3₹116658 Cr25.859.4262.53₹5040 Cr
1,399₹111484 Cr33.089.7757.87₹3879 Cr
2,026.2₹109943 Cr100.556.829.25₹889 Cr
2,500₹101712 Cr49.7913.7571.08₹1913 Cr
1,200.4₹101005 Cr31.355.3263.99₹4196 Cr
1,716₹99253 Cr26.7317.9596.84₹3505 Cr
2,100.7₹96031 Cr17.3730.95154.35₹5333 Cr
1,093.8₹2223 Cr33.467.5847.1₹66 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%

Balance Sheet

Consolidated
Standalone
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018
₹11 Cr₹10 Cr₹10 Cr₹10 Cr₹11 Cr₹6 Cr₹6 Cr₹6 Cr₹9 Cr
₹20 Cr₹5 Cr₹5 Cr₹3 Cr₹2 Cr₹0₹0₹0₹0
₹551 Cr₹490 Cr₹435 Cr₹389 Cr₹382 Cr₹193 Cr₹203 Cr₹187 Cr₹117 Cr
₹551 Cr₹490 Cr₹435 Cr₹389 Cr₹382 Cr₹193 Cr₹203 Cr₹187 Cr₹117 Cr
₹581 Cr₹506 Cr₹450 Cr₹402 Cr₹395 Cr₹199 Cr₹210 Cr₹194 Cr₹125 Cr
₹0₹0₹0₹11 L₹44 L₹83 L₹1 Cr₹6 Cr₹18 Cr
-₹45 L-₹28 L-₹57 L-₹2 Cr-₹2 Cr₹68 L-₹66 L-₹51 L-₹74 L
₹2 Cr₹2 Cr₹2 Cr₹3 Cr₹24 L₹70 L₹1 Cr₹2 Cr₹2 Cr
₹3 Cr₹3 Cr₹2 Cr₹2 Cr₹2 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr
₹5 Cr₹5 Cr₹4 Cr₹3 Cr₹21 L₹4 Cr₹3 Cr₹8 Cr₹21 Cr
₹238 Cr₹178 Cr₹132 Cr₹88 Cr₹63 Cr₹40 Cr₹83 Cr₹58 Cr₹85 Cr
₹48 Cr₹43 Cr₹40 Cr₹32 Cr₹25 Cr₹24 Cr₹21 Cr₹17 Cr₹29 Cr
₹30 Cr₹27 Cr₹0₹0₹5 Cr₹29 Cr₹21 Cr₹17 Cr₹24 Cr
₹4 Cr₹2 Cr₹73 L₹1 Cr₹33 L₹28 L₹41 L₹4 Cr₹5 Cr
₹321 Cr₹249 Cr₹172 Cr₹121 Cr₹94 Cr₹93 Cr₹125 Cr₹96 Cr₹143 Cr
₹907 Cr₹760 Cr₹626 Cr₹527 Cr₹489 Cr₹296 Cr₹338 Cr₹298 Cr₹289 Cr
₹30 Cr₹27 Cr₹11 L₹44 L₹6 Cr₹31 Cr₹27 Cr₹30 Cr₹55 Cr
₹367 Cr₹346 Cr₹275 Cr₹194 Cr₹164 Cr₹184 Cr₹79 Cr₹85 Cr₹104 Cr
₹153 Cr₹122 Cr₹96 Cr₹85 Cr₹73 Cr₹88 Cr₹9 Cr₹21 Cr₹17 Cr
₹213 Cr₹223 Cr₹179 Cr₹109 Cr₹91 Cr₹96 Cr₹70 Cr₹64 Cr₹86 Cr
₹56 Cr₹3 Cr₹6 Cr₹14 Cr₹8 Cr₹4 L₹0₹5 Cr₹11 Cr
₹0₹0₹0₹0₹0₹0₹94 Cr₹101 Cr₹19 L
₹0₹0₹0₹0₹0₹0₹94 Cr₹101 Cr₹19 L
₹5 Cr₹5 Cr₹8 Cr₹43 Cr₹5 Cr₹6 Cr₹5 Cr₹7 Cr₹6 Cr
₹2 Cr₹1 Cr₹2 Cr₹6 Cr₹3 Cr₹0₹13 L₹18 L₹16 L
₹280 Cr₹235 Cr₹194 Cr₹173 Cr₹107 Cr₹102 Cr₹170 Cr₹177 Cr₹145 Cr
₹268 Cr₹223 Cr₹173 Cr₹107 Cr₹65 Cr₹23 Cr₹22 Cr₹21 Cr₹22 Cr
₹62 Cr₹81 Cr₹62 Cr₹75 Cr₹59 Cr₹41 Cr₹49 Cr₹19 Cr₹35 Cr
₹227 Cr₹167 Cr₹136 Cr₹117 Cr₹111 Cr₹79 Cr₹64 Cr₹62 Cr₹67 Cr
₹2 Cr₹16 Cr₹31 Cr₹25 Cr₹114 Cr₹31 Cr₹18 Cr₹13 Cr₹8 Cr
₹2 Cr₹2 Cr₹2 Cr₹1 Cr₹3 Cr₹3 Cr₹46 L₹33 L₹52 L
₹66 Cr₹36 Cr₹27 Cr₹29 Cr₹30 Cr₹17 Cr₹14 Cr₹5 Cr₹12 Cr
₹627 Cr₹525 Cr₹431 Cr₹354 Cr₹382 Cr₹194 Cr₹168 Cr₹120 Cr₹144 Cr
₹306 Cr₹276 Cr₹260 Cr₹232 Cr₹288 Cr₹101 Cr₹43 Cr₹24 Cr₹86 L
₹907 Cr₹760 Cr₹626 Cr₹527 Cr₹489 Cr₹296 Cr₹338 Cr₹298 Cr₹289 Cr
₹266₹239₹214₹191₹180₹311₹327₹302₹218
₹266₹239₹214₹191₹180₹109₹115₹106₹77

Cash Flow

Consolidated
Standalone
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent of Subsidiaries under liquidations
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018
₹87 Cr₹80 Cr₹77 Cr₹57 Cr₹46 Cr₹22 Cr₹25 Cr₹76 Cr₹20 Cr
₹37 Cr₹18 Cr₹7 Cr₹7 Cr₹10 Cr₹36 Cr₹17 Cr-₹34 Cr₹25 Cr
-₹4 Cr-₹9 Cr₹44 Cr₹6 Cr-₹38 Cr-₹40 Cr-₹4 Cr-₹12 Cr-₹5 Cr
₹120 Cr₹89 Cr₹128 Cr₹71 Cr₹18 Cr₹18 Cr₹38 Cr₹31 Cr₹40 Cr
₹105 Cr₹68 Cr₹109 Cr₹61 Cr₹9 Cr₹11 Cr₹25 Cr₹19 Cr₹35 Cr
-₹92 Cr-₹74 Cr-₹92 Cr-₹14 Cr-₹155 Cr-₹20 Cr-₹14 Cr-₹5 Cr-₹11 Cr
-₹13 Cr₹1 Cr-₹15 Cr-₹44 Cr₹130 Cr₹78 L-₹5 Cr-₹6 Cr-₹26 Cr
₹11 L-₹5 Cr₹2 Cr₹3 Cr-₹15 Cr-₹8 Cr₹5 Cr₹7 Cr-₹2 Cr
₹42 L₹5 Cr₹4 Cr₹57 L₹16 Cr₹18 Cr₹13 Cr₹7 Cr₹9 Cr
₹0₹0₹0₹0₹0₹6 Cr₹0-₹1 Cr₹0
₹54 L₹42 L₹5 Cr₹4 Cr₹57 L₹16 Cr₹18 Cr₹13 Cr₹7 Cr

Fundamental Ratios

Consolidated
Standalone

Share Price Live Stats

Open (₹)1,070.20
Volume (₹)53,563.00
High (₹)1,099.00
Upper Circuit1,292.90
Low (₹)1,065.45
Lower Circuit862.00
Prev Close1,077.45
52W High (₹)1,181.90
Price1,093.80
52W Low (₹)697.40

Share Market Cap & Key Ratios Overview

M.Cap (₹)2223.45 Cr
Div. Yield (%)0.58
PE Ratio33.46
Debt to Equity0.05
Price to Book2.77
Book Value265.88
EPS (TTM)32.20
Face Value5.00
ROE (%)12.52

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
WINDLASNSE
LTP
1W Low
1W High
Market cap (₹)
1849.9+12.6 (0.69%)
1832.20
1891.50
4,47,476Cr
9602+227 (2.42%)
9312.50
9740
2,54,764Cr
4928.5+88.5 (1.83%)
4848.50
5010
1,89,423Cr
1180.3+20.3 (1.75%)
1152.10
1190.60
1,16,658Cr
1399+4.5 (0.32%)
1364.50
1419
1,11,484Cr
2026.2+72.2 (3.69%)
1963.80
2055.30
1,09,943Cr
2500+199.3 (8.66%)
2303
2504.30
1,01,712Cr
1200.4+15.4 (1.30%)
1185
1222
1,01,005Cr
1716-18 (-1.04%)
1689.30
1740
99,253Cr
2100.7+17.7 (0.85%)
2080
2135
96,031Cr
1093.8-15.65 (-1.41%)
1065.45
1148
2,223Cr

Windlas Biotech Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹29.64Cr; with other income of ₹4.35Cr, profit before interest and tax came to ₹21.64Cr. Interest expense was ₹1.48Cr; PBT before exceptional items stood at ₹20.16Cr. Cost mix (full year): raw materials ₹534.5Cr; employee cost ₹152.09Cr; depreciation ₹8Cr; other expenses ₹213.21Cr. Basis: consolidated annual results.

Windlas Biotech Ltd Quaterly Results Key Takeaways

Windlas Biotech Ltd reported ₹238.5Cr total income from operations in Mar 2026, softer than ₹233.1Cr in Dec 2025 but higher than ₹202.71Cr in Mar 2025. Operating profit (before other income, interest and exceptional items) was ₹29.64Cr; with other income of ₹4.35Cr, profit before interest and tax came to ₹21.64Cr. Interest expense was ₹1.48Cr, taking profit before tax to ₹20.16Cr. After tax of ₹4.17Cr, profit after tax stood at ₹15.99Cr (vs ₹15Cr in Dec 2025 and ₹16.28Cr in Mar 2025).